News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Palantir trades at rich multiples but is converting commercial traction, recurring government revenue, and rising free cash flow into an AI platform.
  • Analysts argue growth investors should pay up now for Palantir's AI-driven scale and provided entry, stop, and target guidance.
  • SoFi has retraced roughly 50% from last year's peak amid macro and rate fears, despite intact member and product growth.
  • A mid-term SoFi long trade is proposed: entry $15.20, target $22.00, stop $13.50, horizon 45 trading days.
  • Short interest in SoFi is elevated, highlighting crowding and potential volatility.

Latest Articles

Octave Intelligence: Efficiency Gains Are Real, Revenue Lift Is Still a Question - A Mid-Trade Buy on Improvement, Not Idyllic Growth

Octave Intelligence: Efficiency Gains Are Real, Revenue Lift Is Still a Question - A Mid-Trade Buy on Improvement, Not Idyllic Growth

Octave Intelligence is executing sensibly on AI-enabled efficiency products that are reducing costs and increasing recurring revenue, but recent results show total revenue slipping and management has not yet demonstrated that AI is reliably driving top-line expansion. The stock trades at a reasonable multiple with a $5.06B market cap; this trade bu…

Buy for Yield, Expect a Bumpy Road: Delek Logistics After the Secondary

Buy for Yield, Expect a Bumpy Road: Delek Logistics After the Secondary

Delek Logistics (DKL) yields ~8.3% after a dilutive 4 million-share offering at $50. Management is using proceeds to pay down debt and accelerate separation from its sponsor. The stock trades at a roughly $3.1B market cap with EV/EBITDA ~16.6x and FCF roughly $134M — attractive numbers for an asset-light midstream with strong third-party exposure, …

UnitedHealth: Buy for Reliable Cash Flow and a Growing Optum Engine

UnitedHealth: Buy for Reliable Cash Flow and a Growing Optum Engine

UnitedHealth (UNH) offers a pragmatic long trade: a $377 entry with a $420 target and $345 stop. The thesis rests on sizeable free cash flow ($23.6B), a diversified earnings engine (UnitedHealthcare + Optum), a healthy balance sheet (debt/equity ~0.74) and a 2.38% yield that compounds while the company invests in analytics and specialty pharmacy. T…

Astro Digital, Premier Builder of Satellites for Commercial, Civil and Defense Applications, to Become Public Through Merger with Proem Acquisition Corp I

Astro Digital, Premier Builder of Satellites for Commercial, Civil and Defense Applications, to Become Public Through Merger with Proem Acquisition Corp I

Astro Digital, a U.S.-based satellite technology company, announced a definitive merger agreement with Proem Acquisition Corp I (Nasdaq: PAAC), a special purpose acquisition company, to become a publicly traded company on the Nasdaq. The merger values Astro Digital at approximately $587 million and will provide about $180 million in gross proceeds …

Genius Group Announces 140% Increase in Revenue, $6.4 Million Net Profit from Operating Units, 79% Reduction in Total Net Loss in First Half of 2026

Genius Group Announces 140% Increase in Revenue, $6.4 Million Net Profit from Operating Units, 79% Reduction in Total Net Loss in First Half of 2026

Genius Group Limited announced a 140% increase in revenue to $6.2 million and a net profit of $6.4 million from operating units in the first half of 2026, alongside a 79% reduction in total net loss to $4 million. The company restructured by closing loss-making divisions, drastically reducing third-party debt by 99%, and focusing on its core operat…

NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212

NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212

NeOnc Technologies Holdings, a clinical-stage biopharmaceutical company focused on CNS cancers, announced an upcoming FDA End-of-Phase 1 meeting for its investigational drug NEO212. The company will seek FDA feedback on patient population, trial design, dose selection, and potential accelerated approval pathways following encouraging clinical activ…

NETSOL Technologies reports record fiscal 2026 revenue and full-year profitability, exceeding guidance

NETSOL Technologies reports record fiscal 2026 revenue and full-year profitability, exceeding guidance

NETSOL Technologies, Inc. announced record fiscal 2026 financial results with a 12.5% increase in revenue to $74.4 million, nearly doubling operating income year-over-year, and achieving strong cash flow and margin expansion. The company exceeded its guidance with robust growth in subscription and support revenues, improved gross margins, and incre…

Harvard Ave Acquisition Corporation and OAG International Ltd Announce Definitive Business Combination Agreement

Harvard Ave Acquisition Corporation and OAG International Ltd Announce Definitive Business Combination Agreement

Harvard Ave Acquisition Corporation (HAVA) has entered a definitive business combination agreement with OAG International Ltd, a global provider of specialized pipeline construction and integrity services. The merger will result in OAG Pipeline Technologies Inc., a Nasdaq-listed public company focused on expanding pipeline technology capabilities a…

NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes

NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes

NewcelX Ltd. (Nasdaq: NCEL), a regenerative medicine biopharmaceutical company focused on stem-cell therapies for Type 1 Diabetes (T1D), announced attendance of its senior management at the upcoming Breakthrough T1D Clinical & Research Congress. The company will discuss its lead program, NCEL-101, and preparations for a planned Phase 1/2a clinical …

Newtek Bank Expands Connected Banking Capabilities Across Leading Accounting and Business Applications

Newtek Bank Expands Connected Banking Capabilities Across Leading Accounting and Business Applications

NewtekOne's banking subsidiary, Newtek Bank, has expanded its connectivity with major accounting and business applications, including Sage, Xero, FreshBooks, and Restaurant365, complementing existing integrations with QuickBooks. This enhancement allows small business clients to better integrate banking, payments, and payroll data within their pref…

ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

ALX Oncology announced the publication in Nature Medicine of positive Phase 2 clinical trial results (ASPEN-06) demonstrating that evorpacept combined with trastuzumab, ramucirumab, and paclitaxel significantly improved response rates in patients with HER2-positive gastric cancer compared to control treatments. The data revealed a 40.3% objective r…

COMSTOCK ANNOUNCES SIGNING OF FRAMEWORK AGREEMENT FOR $1.65 BILLION STRATEGIC PARTNERSHIP WITH SOCAR

COMSTOCK ANNOUNCES SIGNING OF FRAMEWORK AGREEMENT FOR $1.65 BILLION STRATEGIC PARTNERSHIP WITH SOCAR

Comstock Resources, Inc. announced a $1.65 billion strategic partnership agreement with Azerbaijan's SOCAR to jointly develop the Haynesville Shale natural gas assets. The agreement includes plans for SOCAR to market natural gas as LNG internationally, leveraging the assets' proximity to Gulf export facilities. The definitive purchase agreement is …

4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

4D Molecular Therapeutics (Nasdaq: FDMT) announced the initiation of the global Phase 3 4SIGHT clinical trial for its lead product candidate, 4D-150, targeting diabetic macular edema (DME), a large and underserved retinal disease market. This follows encouraging two-year results from the SPECTRA trial demonstrating safety, durable vision improvemen…

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

Keros Therapeutics, a clinical-stage biopharmaceutical company, announced dosing of the first patient in its Phase 2 trial evaluating rinvatercept in patients with Duchenne muscular dystrophy (DMD). The trial aims to assess safety, tolerability, and functional improvements in late-ambulatory and early non-ambulatory DMD patients, signaling progress…